Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma

Pembrolizumab has been available for the treatment of radical resectable urothelial carcinoma (UC) when it is exacerbated after chemotherapy since December 2017 in Japan. However, the efficacy of chemotherapy for cases progressing after pembrolizumab is unclear. The present study compared the outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Furubayashi, Nobuki, Hori, Yoshifumi, Morokuma, Futoshi, Tomoda, Toshihisa, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Kuroiwa, Kentaro, Tokuda, Noriaki, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976390/
https://www.ncbi.nlm.nih.gov/pubmed/33767860
http://dx.doi.org/10.3892/mco.2021.2253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976390/
https://www.ncbi.nlm.nih.gov/pubmed/33767860
http://dx.doi.org/10.3892/mco.2021.2253

Ejemplares similares